Abstract The energetics of transmembrane (TM) helix dimerization in membranes and the thermodynamic principles behind receptor tyrosine kinase (RTK) TM domain interactions during signal transduction can be studied using Förster resonance energy transfer (FRET). For instance, FRET studies have yielded the stabilities of wild-type fibroblast growth factor receptor 3 (FGFR3) TM domains and two FGFR3 pathogenic mutants, Ala391Glu and Gly380Arg, in the native bilayer environment. To further our understanding of the molecular mechanisms of deregulated FGFR3 signaling underlying different pathologies, we determined the effect of the Gly382Asp FGFR3 mutation, identified in a multiple myeloma cell line, on the energetics of FGFR3 TM domain dimerization. We measured dimerization energetics using a novel FRET acquisition and processing method, termed ''emission-excitation FRET (EmEx-FRET),'' which improves the precision of thermodynamic measurements of TM helix association. The EmEx-FRET method, verified here by analyzing previously published data for wild-type FGFR3 TM domain, should have broad utility in studies of protein interactions, particularly in cases when the concentrations of fluorophore-tagged molecules cannot be controlled.
Introduction
The receptor tyrosine kinase (RTK) family comprises a large group of single-pass membrane proteins that conduct biochemical signals upon dimerization in the plasma membrane (Fantl, Johnson and Williams 1993) . The dimerization process brings the catalytic domains in close proximity and results in their cross-phosphorylation and activation (Schlessinger 2000; van der Geer, Hunter and Lindberg 1994) . RTKs regulate cell growth, differentiation and metabolism; and their deregulation leads to pathologies (Blume-Jensen and Hunter 2001) . Functional defects can arise due to chromosomal translocations, protein overexpression or the occurrence of missense gain-of-function mutations. Often, such missense mutations occur in the transmembrane (TM) domains of RTKs. Two mechanisms have been proposed to contribute to pathogenesis due to RTK TM mutations Cho et al. 2004 ): (1) direct dimer stabilization of the TM domain dimers, mediated by hydrogen bonds, disulfide bonds and cation-p interactions, and (2) defects in the downregulation of the activated receptor dimers in the cell. The relative importance of these two mechanisms in pathogenesis has not been explored in detail. Furthermore, it is not known if a specific mutation can affect both dimer stability and downregulation efficiency. Previously, we characterized the stability of the wild-type (WT) fibroblast growth factor receptor 3 (FGFR3) TM domain dimer as well as two pathogenic dimers . FGFR3 is an RTK that plays an important role in human skeletal development (Deng et al. 1996) , and the studied mutations are associated with skeletal dysplasias. The first one, Ala391Glu, is linked to Crouzon syndrome with acanthosis nigricans, an autosomal dominant disorder characterized by premature ossification of the skull (craniosynostosis) (Meyers et al. 1995) , accompanied by skin hyperpigmentation and thickening (hyperkeratosis), as well as to bladder cancer (van Rhijin et al. 2002) . The second one, Gly380Arg, is linked to achondroplasia (Shiang et al. 1994; Webster and Donoghue 1996) , the most common form of human dwarfism, characterized by short stature (Vajo, Francomano and Wilkin 2000) , and is also found in some cancers (van Rhijin et al. 2002) . We have shown that while the Ala391Glu mutation stabilizes the FGFR3 TM domain dimer by -1.3 kcal/mol Merzlyakov et al. 2006) , the achondroplasia mutation, Gly380Arg, does not alter the stability of the FGFR3 TM domain dimer .
Such studies of dimerization propensities of isolated RTK TM domains and their pathogenic mutants can provide insights into pathogenesis mechanisms. If the isolated RTK TM dimer is stabilized due to a particular mutation, it could be expected that this mutation stabilizes the active dimeric state of the whole receptor. If, however, the mutation has no effect on TM dimer stability, other mechanisms of pathogenesis, such as slow downregulation of the activated receptors, are likely at play. Therefore, comparative studies of TM dimer stabilities can help us uncover the relative importance of direct stabilization of RTK dimers in various pathologies.
Here, we investigated a Gly382Asp mutant identified in a multiple myeloma cell line (Otsuki et al. 1998) . We found that the Gly382Asp mutation does not stabilize the FGFR3 TM dimer. This finding is consistent with a published structural model of the FGFR3 TM domain dimer , in which Gly382 does not participate in the helix-helix contacts. Therefore, pathogenesis associated with the Gly382Asp mutation is likely not due to dimer stabilization. The exact role of the mutation in multiple myeloma pathogenesis is yet to be identified.
We also present a novel robust Förster resonance energy transfer (FRET) acquisition and processing method that gives the free energy of dimerization of TM helices with high precision. The method that we describe, termed ''emission-excitation FRET'' (EmEx-FRET), relies on the acquisition of both emission and excitation spectra. These two spectra are combined with standard donor-only and acceptor-only emission and excitation spectra to yield the actual donor and acceptor concentration, the FRET efficiency and the free energy of dimerization. We verified the EmEx-FRET method using previously published data for the WT FGFR3 TM domain and used it to determine the dimerization energetics of the Gly382Asp mutant.
The EmEx-FRET method presented here provides a tool to efficiently probe the stability of TM helix dimers, including RTK TM domain dimers and their pathogenic mutants. The method reduces experimental uncertainties due to sample-to-sample variations in protein concentrations as a result of the very low solubility of the hydrophobic TM helices. In addition, this method can have broad utility when the concentrations of the donor-and acceptor-tagged molecules cannot be controlled, such as in cellular studies.
Materials and Methods

Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased from Avanti (Birmingham, AL). The 33-amino acid-long TM domain of FGFR3 (TM WT , sequence RRAGSVYAGILSYGVGFFLFILVVAAVTLCRLR, and the pathogenic mutant TM 382Asp , sequence RRAGSVYA-GILSYGVDFFLFILVVAAVTLCRLR) were synthesized using solid-phase peptide synthesis, as described previously Iwamoto et al. 2005 ). The peptides were purified using reverse-phase high-performance liquid chromatography (HPLC; Varian Analytical Instruments, Walnut Creek, CA) using a water/acetonitrile gradient. Matrix Assisted Laser Desorption/LonizationTime of Flight mass spectrometry confirmed the correct molecular weight of the peptides. The single Cys residue in the peptide was labeled with fluorescein-maleimide (donor) and rhodamine-maleimide (acceptor) (Molecular Probes, Eugene, OR) and purified as previously described Li and Hristova 2004) .
Vesicle Preparation and FRET Measurements
Lipids in chloroform and peptides in hexafluoro-2-propanol were mixed, as described . The organic solvents were removed under a steam of nitrogen gas; the mixture was lyophilized and then redissolved in 10 mM phosphate buffer and 500 mM NaCl (pH 7) to a concentration of 0.25 mg/ml of lipids. Samples were freezethawed several times before the FRET experiments, as discussed in detail elsewhere .
Emission and excitation spectra of labeled peptides in vesicles were measured using a Fluorolog 3-22 fuorometer (Jobin Yvon, Edison, NJ). The vesicle solution was placed in a 10 · 2 mm quartz cuvette (Starna Cells, Atascadero, CA). For the emission scans, the excitation wavelength was set at 439 nm and the emission intensity was collected at 450-700 nm. In the excitation scans, the emission intensity was collected at 595 nm and the excitation wavelength was scanned at 400-570 nm.
The EmEx-FRET Method
Overview
The method that we introduce, EmEx-FRET, relies on the acquisition of both excitation and emission spectra for the ''FRET sample,'' i.e. the liposomal solution containing both donor-labeled and acceptor-labeled TM helices. Furthermore, both excitation and emission spectra need to be acquired for donor-only and acceptor-only ''standards'' of well-known donor and acceptor concentrations. In the EmEx-FRET method, we rely on these standard spectra to calculate not only the FRET efficiency but also the actual donor and acceptor concentration and, therefore, the equilibrium constants and the free energy of lateral dimerization with high experimental precision. As discussed below, uncertainties in actual donor and acceptor concentrations, due to sample-to-sample variations as a result of low peptide solubility, can be resolved and just a few spectra are sufficient to reliably determine the energetics of interactions.
Theory
The efficiency of energy transfer, E, from an excited donor to an acceptor is defined as follows (Lakowicz 1999 ):
where F DA and F D denote the donor emission in the presence and in the absence of an acceptor, respectively, and k D em is the wavelength of the maximum donor emission (see Fig. 1B ). Similarly, F AD and F A will be used to denote the acceptor emission in the presence and in the absence of a donor. F DA (just as F D , F A , F AD , etc.) denotes the complete emission spectra, while F DA (k D em ) refers to the fluorescence intensity value at k D em . When both the donor and the acceptor are present, we can write the following: À Á are the extinction coefficients of the donor and the acceptor at k D ex (see Fig. 1 ), S D and S A are scaling factors which depend on the quantum yields of the donor and acceptor, the photodetector efficiencies at k D em and k A em and the geometry of the experimental setup. At zero FRET efficiency (E = 0), the donor and the acceptor emit due to direct excitation only, such that F DA = F D and F AD = F A . At non-zero FRET efficiency (E " 0), part of the energy, absorbed by the donor, is transferred to the acceptor. The donor fluorescence is quenched (F DA < F D ), and the acceptor fluorescence is enhanced (F AD > F A ). The acceptor enhancement, termed ''sensitized fluorescence'' (F sen ), can be calculated as follows:
The donar quenching is given by the following:
Therefore, the efficiency of donor quenching at k D em is proportional to the sensitized acceptor fluorescence at k A em , with S D /S A being the scaling factor.
The scaling factor S D /S A depends on the dyes used and on the characteristics of the instrument, not on the particular dye concentration. S D /S A can be calculated from the FRET spectrum in a system of well-defined dye concentrations and known FRET efficiency according to the following:
Alternatively, if the photodetector efficiency at k D em and k A em is the same (or if the fluorescence signal is normalized by the photodetector efficiency), then S D /S A equals the ratio of donor and acceptor quantum yields, u D /u A , which can be calculated from measured absorbance and emission spectra.
Once S D /S A is determined, it can be used to calculate the donor fluorescence in the absence of the acceptor (i.e., the donor control, F D ) from the measured donor fluorescence in the presence of the acceptor F DA according to the following:
The Donor and Acceptor Standards Figure 1 shows the excitation and the emission spectra of the fluorescein/rhodamine FRET pair, conjugated to the WT FGFR3 TM domain. The amplitudes of these spectra depend on the total three-dimensional (3D) concentration of the fluorophores (i.e., moles of labeled peptides per unit volume). The FRET efficiencies and the dimerization energetics in liposomes, however, are determined solely by the protein-to-lipid ratio . Therefore, experiments could be carried out at various protein and lipid 3D concentrations and then interpreted with respect to the protein-to-lipid ratio. Alternatively, all experiments can be performed at fixed lipid 3D concentration, by varying the protein concentration (the protein-to-lipid ratio). The latter is the approach that we have taken in this work. In all experiments, the lipid concentration was fixed at 0.25 mg/ ml (0.325 mmolar POPC solution). The protein concentration was varied and is reported in mol% (moles of protein per mole of lipid). The blue lines in Figure 1 were recorded for 0.1 mol% Fl-TM WT , while the red lines are for 0.1 mol% Rhod-TM WT . Inspection of the excitation spectra in Figure 1A reveals that at excitation wavelength k A ex the acceptor excitation reaches its maximum, while the donor excitation is negligible. Thus, the fluorescence of the acceptor at k A ex in the presence and absence of the donor is the same (i.e., the black and the blue spectra coincide at k A ex ; see Fig. 1A ). This spectral feature is crucial for the applicability of the EmEx-FRET method. We point out that this is a feature of many FRET pairs, such as Cy3 and Cy5, YFP and Cherry, etc. Thus, the EmEx-FRET method that we introduce is not restricted to fluorescein and rhodamine but has a broad utility.
The excitation and emission spectra of the donor only (blue lines) and acceptor only (red lines) in Figure 1 are used as ''standard'' spectra in the EmEx-FRET method and are referred to as ''excitation and emission standards.'' The amplitudes of the standard spectra should be known with high accuracy. Therefore, multiple measurements at different dye concentrations are recommended to generate these standards. The spectra of the fluorophores are usually environment-sensitive, and the standard spectra should be acquired under exactly the same conditions (pH, lipid composition, etc.) as those used for acquisition of the FRET spectra. Once the standard spectra are available, the spectrum of every sample containing both donor and acceptor (i.e. every ''FRET sample'') can be used to calculate the actual donor and acceptor concentrations in the sample, the FRET efficiency and the free energy of interactions using the EmEx-FRET protocol described below.
The EmEx-FRET Protocol
Step 1 A solution of liposomes containing donor-labeled and acceptor-labeled TM domains (i.e. a ''FRET sample'') was prepared as previously described , and the excitation and emission spectra were acquired as discussed in Materials and Methods. Each FRET spectrum (i.e., the spectrum of the FRET sample) has three contributions: direct donor emission in the presence of the acceptor F DA , direct acceptor emission F A and sensitized acceptor emission F sen . Furthermore, F AD = F A + F sen .
Step 2 The acquired FRET excitation spectrum ( Fig. 2A , black line) is compared to the standard excitation spectrum of the acceptor (Fig. 1A, red line) . The standard spectrum is multiplied by a coefficient, n, to produce the red line in Figure 2A , such that the amplitude of the scaled standard ( Fig. 2A, red line) is identical to the FRET excitation spectrum ( Fig. 2A , black line) at k A ex This step gives the concentration of the acceptor in the sample, [a], as n times the standard acceptor concentration, in this case n · 0.1 mol%.
Step 3 The emission standard of the acceptor (Fig. 1B , red line) is multiplied by n to obtain the direct emission contribution of the acceptor (Fig. 2B, red line) . The direct acceptor contribution (red line) is subtracted from the FRET emission spectrum (Fig. 2B, black line) , to reveal the sum of the direct donor emission and the sensitized acceptor emission, F DA + F sen . This sum is plotted in Figure 2C with the black dashed line.
Step 4 The emission standard spectrum of the donor (Fig. 1B, blue line) is multiplied by a coefficient to produce the blue dashed line in Figure 2C , such that the amplitude of the scaled standard (blue dashed line) is identical to the black dashed line in Figure 2C at k Step 5 The value DF D (k D em ), determined in step 4, is added to F DA (k D em ) (Fig. 2D) to give the value of the donor emission in the absence of acceptor at k (Fig. 2D, blue line) as the emission of the donor standard (Fig. 1B, blue line) Thus, we determine not only the FRET efficiency (step 5) but also the donor concentration (step 5) and the acceptor concentration (step 1).
Further Data Analysis
Knowledge of the FRET efficiency and the donor and acceptor concentrations allows calculation of equilibrium constants describing TM helix dimerization. As discussed previously , the measured FRET efficiency, E, has two contributions, one due to random colocalization of donors and acceptors (proximity effects) and one due to sequence-specific interactions:
The FRET efficiency due to the proximity effect, E proximity , is a function of the acceptor concentration [a] and can be calculated as outlined in detail elsewhere . The FRET efficiency due to specific oligomerization, E oligomer , can be presented as follows:
where f O is the fraction of molecules in the oligomeric state, p D is the probability for donor quenching in the oligomer and E R is the FRET efficiency in the oligomer. If the oligomers are much smaller than the Förster radius, then E R = 1. The probability of a donor-labeled molecule dimerizing with another donor-labeled or unlabeled molecule is 1 -x A , where x A is the fraction of the acceptor-labeled molecules, x A ¼ ½a ½d=f d þ½a=f a , and f d and f a are the donor and acceptor labeling yields. The probability of a donor-labeled molecule oligomerizing only with donor-labeled or unlabeled molecules is (1 -x A ) n-1 , where n is the number of molecules in the oligomer. Any donor will be quenched if it oligomerizes with at least one acceptor and therefore:
Since [a] and [d] can be determined using the EmEx-FRET method for each sample, E proximity and x A can be calculated too, such that the fraction of molecules in the oligomeric state and the number of molecules in the oligomer can be calculated.
In 
Results
EmEx-FRET Method Verification
To verify the EmEx-FRET method, we used previously published data for the WT FGFR3 TM domain ( and Hristova 2006). The dimerization energetics for WT is well characterized, based on an extensive study comprising multiple measurements for various peptide-to-lipid ratios and donor-to-acceptor ratios. We used these data in the following way. First, we determined the ratio S D /S A from averaged FRET spectra for 0.08, 0.2, 0.25 and 0.3 mol% peptide, donor-to-acceptor ratio = 1, using Eq 6. Next, we used the calculated S D /S A and the EmEx-FRET method, as described in Materials and Methods, to analyze the FRET spectra acquired for 0.1 and 0.4 mol% peptide and calculated the anticipated donor-only control (donor fluorescence in the absence of the acceptor, F D ). Finally, the calculated donor-only control was compared to the experimental donor-only control (see Fig. 3 ). S D /S A for the fluorescein-rhodamine FRET pair was determined from Eq. 6 to be 1 ± 0.05. As discussed in Materials and Methods, S D /S A can be determined alternatively by measuring the quantum yields of the donor and acceptor, u D and u A , at k D em and k A em , respectively. The quantum efficiency of the photodetector used at these wavelengths was practically the same, such that S D / S A = u D /u A . From measurements of ultraviolet absorbance and fluorescence spectra (not shown), we obtain u D / u A = 1.06 ± 0.1, similar to a published value of u D / u A = 1.02 ± 0.04 (Magde, Wong and Seybold 2002) .
Based on all these measurements, a value of S D /S A = 1.0 was chosen to calculate the anticipated donor fluorescence in the absence of the acceptor from the experimental FRET spectra for 0.1 and 0.4 mol% WT. Figure 3A and B shows the experimental F DA spectra (solid lines), the calculated anticipated F D spectra (dotted lines) and the experimental F D control spectra (dashed lines) for 0.1 and 0.4 mol% WT, respectively. Comparison of the dashed and dotted lines shows that the calculated F D spectra are within 2% of the experimental donor-only controls, validating the EmEx-FRET method.
We further showed that the EmEx-FRET method allows accurate calculation of the free energy of dimerization, even from a single experiment. A FRET spectrum (solid line) and an experimental donor-only control (dashed line) are shown in Figure 4 . The FRET spectrum was measured for a single sample, a liposomal solution with 0.15 mol% (intended) fluorescein-labeled TM WT and 0.15 mol% (intended) rhodamine-labeled TM WT . The calculation of the dimerization free energy based on donor quenching from the two experimental spectra in Figure 4 , a method that we have used previously to calculate the free energy of dimerization , gives -1.8 kcal/mol (the detailed protocol for such calculations has been published elsewhere You et al. 2005] ). This value is different from the value obtained in an extended experimental study, based on multiple measurements at various peptide concentrations, -2.8 ± 0.1 kcal/mol . Using the FRET emission spectrum (solid line), the FRET excitation spectrum (not shown) and the EmEx-FRET method, we determined the ''actual'' concentrations of FL-TM WT and Rhod-TM WT to be 0.172 mol% and 0.123 mol%, and we calculated the dimerization free energy as -2.9 kcal/mol, which is within experimental error of the published value of -2.8 ± 0.1 kcal/mol .
EmEx-FRET analysis of the FRET spectrum in Figure 4 demonstrates that the fluorophore concentrations in the sample are different from the intended 0.15 mol%. As a result, the donor-to-acceptor ratio is 1.4 instead of 1, thus affecting the free energy calculations. Furthermore, the experimental florescein-only control (dashed line) is not the appropriate one since the concentration of the donor in the ''FRET sample'' is higher than intended. The incorrect donor and acceptor concentrations and the improper florescein-only control lead to an inaccurate free energy calculation, -1.8 kcal/mol. The basis of the error is the limited experimental precision in the preparation of samples of well-defined donor and acceptor concentrations, due to , we determine, from the decrease in donor quenching, the dimerization free energy as -1.8 kcal/mol. Using the FRET spectrum and the EmEx-FRET method, we calculate the ''actual'' concentrations of Fl-TM WT and Rhod-TM WT as 0.172 mol% and 0.123 mol%, respectively, and the dimerization free energy as -2.9 kcal/mol. The value from an extended experimental study, based on multiple measurements at various peptide concentrations, is -2.8 ± 0.1 kcal/mol sample-to-sample variation and/or incomplete solubilization of the very hydrophobic peptides. However, the actual concentrations of donor-and acceptor-labeled peptides and the appropriate donor-only control (dotted line) can be calculated using the EmEx-FRET method, thus yielding the correct dimerization free energy.
Dimerization Energetics of Gly382Asp FGFR3 TM Domain
Next, we investigated the effect of the Gly382Asp mutation, identified in the KSM-18 myeloma cell line (Otsuki et al. 1998) , on the dimerization propensity of FGFR3 TM domain. While cellular studies have produced contradictory results about the effect of the mutation on receptor activation (Ronchetti et al. 2001) , biophysical studies of the mutant Gly382Asp TM domain have never been carried out. Here, we characterized the dimerization energetics of the mutant TM domain, TM 382Asp , and compared it to published data for WT . POPC liposomes containing donor-and acceptor-labeled TM 382Asp were prepared as described in Materials and Methods. Experiments were set up with total TM 382Asp concentrations varying between 0.05 and 0.5 mol%, a concentration range shown to be optimal for FRET measurements You et al. 2005) . Altogether, six different FRET samples were prepared at various peptideto-lipid ratios, donor-to-acceptor ratio = 1, and both emission and excitation spectra were acquired for all of them. Figure 5 shows the ''raw'' fluorescence spectra for two different TM 382Asp concentrations. From such spectra, the FRET efficiencies, E, and the actual donor and acceptor concentrations, [d] and [a] , were determined using the EmEx-FRET method; the actual concentrations were within 20% of the intended ones. For the EmEx-FRET calculations, we used S D /S A = 1 and the donor and acceptor standards established for the WT FGFR3 TM domain. To obtain FRET that is due to sequence-specific dimerization, the contribution from random colocalization, E proximity , was calculated as described in detail elsewhere and subtracted from the measured FRET efficiency to give FRET due to sequence-specific dimerization, E dimer (Eq. 8). We emphasize that the two contributions to the measured FRET efficiencies, one due to specific interactions and one due to random dye colocalization, can be separated only when the acceptor concentration is accurately known.
The dimer fraction [D]/[T] for TM 382Asp was determined using Eq. 9 for E R = 1, corresponding to 100% energy transfer efficiency from the donor to the acceptor in the dimer . The dimer fraction, as a function of total peptide concentration, is shown in Figure 6 . The free energy of dimerization, calculated according to DG = -RT lnK, is -2.78 ± 0.04 kcal/mol. This value is the same as the one determined for WT, -2.8 ± 0.1 kcal/mol , indicating that the Gly382Asp mutation does not stabilize the FGFR3 TM domain dimer.
We note that each symbol in Figure 6 shows the result from a single experiment. Yet, one can have high confidence in the data because the donor and acceptor concentrations, and therefore the total peptide concentrations, were determined using the EmEx-FRET method. Calculation of dimerization free energies from donor quenching (i.e., not using the EmEx-FRET method) gives -2.9 ± 0.7 kcal/mol. Thus, application of the EmEx-FRET method reduces the uncertainty in the free energy calculation from ± 0.7 to ± 0.04 kcal/mol and therefore increases the experimental precision. 
Discussion
The EmEx-FRET Method Equilibrium constants describing TM helix interactions have been previously measured by acquiring either emission You et al. 2006; Merzlyakov et al. 2006) or excitation (Fisher, Engelman and Sturgis 1999) FRET spectra. Experimental challenges can arise because the concentration of donors and acceptors cannot be verified in the ''FRET samples'' (dye:lipid ratios never exceed 1/500 and absorbance measurements lack the requisite sensitivity). Therefore, sample-to-sample variations in protein concentrations due to the very low solubility of the hydrophobic TM helices can introduce uncertainties in the measured FRET efficiencies and the calculated dimerization free energies. The EmEx-FRET method, which gives the free energies of interactions with high precision, involves the acquisition of both emission and excitation spectra. Here, the method was verified using previously published data for the WT FGFR3 TM domain and used to calculate the free energy of dimerization for the Gly382Asp pathogenic FGFR3 mutant as DG = -2.78 ± 0.04 kcal/mol. This value was determined with high precision from single measurements at six peptide-to-lipid ratios. The actual donor and acceptor concentrations were determined for each sample, the dimer fraction was calculated using the actual donor and acceptor concentrations rather than the intended concentrations and the calculated dimer fractions were plotted as a function of the actual total peptide concentration (Fig. 6) . Thus, several sources of statistical error were eliminated, resulting in high experimental precision.
We note that EmEx-FRET analysis is valid only when the fluorescence intensity of the dyes (in the absence of FRET) is linear with dye concentrations. Otherwise, selfquenching or inner filter effects, which occur at high concentrations, impair the quantitative FRET analysis. We have found that self-quenching does not occur for donor concentrations that are lower than 0.3 mol% . Therefore, dye concentrations that exceed 0.3 mol% are not recommended for measurements of TM helix dimerization using FRET.
As discussed above, the standard spectra should be acquired under exactly the same conditions (pH, lipid composition, etc.) as the ones used for the acquisition of FRET spectra. It should be further noted that spectra of free fluorophores cannot be used as standard spectra since they may be altered when the dyes are coupled to the proteins and embedded in the membrane.
The EmEx-FRET method presented here can be useful in cases when the donor and acceptor concentrations, and the total protein concentration, are not controlled or are unknown. Such a situation occurs in cellular studies, when expression of the donor-tagged and acceptor-tagged proteins cannot be controlled. Previously, unknown concentrations have been estimated by photobleaching of the acceptor (Raicu et al. 2005) or of the donor, such that FRET is ''turned off.'' The resulting changes in F DA and F AD can be linked to the actual initial F D and F A values and to the initial FRET efficiency. However, there are several potential problems with such an approach: (1) the bleaching rate of the free dyes and of dyes in the donor-acceptor complexes could be different; (2) donor and acceptor spectra are often not well separated, such that the dyes cannot be bleached independently; and (3) photoconversion during bleaching may impair further calculations. The EmEx-FRET method is free from such problems and, thus, could have applications in cases when the bleaching approach is not optimal.
The FGFR3 Gly382Asp Mutation
The Gly382Asp mutation in the TM domain of FGFR3 has been identified in the KSM-18 multiple myeloma cell line (Otsuki et al. 1998) . Unlike other FGFR3 mutations, it has not been so far identified in skeletal disorders. The mutation does not affect FGFR3 activity in the KSM-18 cell line, and it is not capable of inducing foci formation in NIH . Symbols represent the dimer fractions calculated using the EmEx-FRET method, for different protein concentrations. Solid line is the theoretical equilibrium curve, obtained as described in detail previously . The free energy of dimerization, as the average of the six experiments, is -2.78 ± 0.04 kcal/mol. For comparison, the average free energy value, obtained from donor quenching as previously described ) (i.e., not using the EmEx-FRET method), is -2.9 ± 0.7 kcal/ mol. Thus, the EmEx-FRET method increases the precision of TM helix dimerization energetics measurements 3T3 cells (Ronchetti et al. 2001) . These findings are consistent with our results, which demonstrate that the mutation does not affect the dimerization energetics of FGFR3 TM domain. A previously published model of the FGFR3 TM domain, created with the software CHI (Adams et al. 1995) , identifies the residues that mediate helix-helix contact to be Leu377, Val381, Phe384 and Ile387 . In this model, Gly382 does not interact with the neighboring helix and is exposed to lipids. Based on this model, it can be expected that substitution of Gly382 with any other amino acids does not affect dimer stability, consistent with our findings. We note that the Gly382Asp mutation differs from the Crouzon Ala391Glu mutation, which stabilizes the FGFR3 TM dimer by -1.3 kcal/mol. It has been proposed that Glu in position 391 forms a hydrogen bond with the neighboring helix in the FGFR3 dimer . However, Asp in position 382 does not appear to participate in stabilizing hydrogen bonding interactions. Ronchetti et al. (2001) found that, in transfected 293T cells, the Asp382 mutant activates the mitogen-activated protein kinase pathway in a ligand-independent manner, while the WT required ligands. This result demonstrates that the Gly382Asp mutation is capable of causing overactivation, despite the fact that it does not stabilize the dimer. It can be therefore hypothesized that other mechanisms of pathogenesis are at play. In this respect, the Gly382Asp mutation is similar to the achondroplasia Gly380Arg mutation, which does not affect FGFR3 TM dimer stability but causes deregulated signaling. Some RTK mutations have been shown to induce slow downregulation of the activated receptor dimers, resulting in prolonged signaling. Examples include the achondroplasia mutation in the TM domain and the thanatophoric dysplasia II Lys650Glu mutation in the catalytic domain of FGFR3 (Cho et al. 2004 ). Thus, dimer stabilization is not necessarily required for pathogenesis. It is possible that the Gly382Asp mutation also compromises the downregulation of FGFR3. Indeed, immunofluorescence studies of the localization of the Gly382Asp receptor have revealed intense cytoplasmic staining (Ronchetti et al. 2001) .
In model bilayers, the achondroplasia mutation has been shown to induce a shift in the hydrocarbon core embedded segment of FGFR3 TM domain (X. Han et al. 2006) . Based on this result, we previously hypothesized that a mutationinduced change in membrane topology may be the structural basis for the slow receptor downregulation in achondroplasia. Asp382 is not expected to participate in the dimer interface and is likely exposed to lipids, which is energetically unfavorable and may lead to changes in membrane topology. Future structural studies of the Gly382Asp mutant in bilayers, as well as cellular studies that address the fate of the Gly382Asp activated receptors, should shed further light on the role of the Gly382Asp mutation in multiple myeloma pathogenesis.
